Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO William J. Peters Sells 4,231 Shares

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO William J. Peters sold 4,231 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the transaction, the chief financial officer now owns 97,363 shares of the company’s stock, valued at approximately $2,681,377.02. This represents a 4.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Amphastar Pharmaceuticals Trading Up 1.7 %

Shares of Amphastar Pharmaceuticals stock opened at $28.81 on Friday. The stock has a market capitalization of $1.37 billion, a P/E ratio of 9.60, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The company has a 50-day simple moving average of $33.71 and a 200 day simple moving average of $41.97. Amphastar Pharmaceuticals, Inc. has a 12-month low of $26.98 and a 12-month high of $53.96.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Asset Management One Co. Ltd. bought a new stake in Amphastar Pharmaceuticals during the 3rd quarter worth about $78,000. Assetmark Inc. grew its holdings in Amphastar Pharmaceuticals by 9.1% during the 3rd quarter. Assetmark Inc. now owns 43,906 shares of the company’s stock worth $2,131,000 after acquiring an additional 3,650 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in Amphastar Pharmaceuticals during the 3rd quarter worth about $785,000. GSA Capital Partners LLP bought a new stake in Amphastar Pharmaceuticals during the 3rd quarter worth about $303,000. Finally, Victory Capital Management Inc. grew its holdings in Amphastar Pharmaceuticals by 10.9% during the 3rd quarter. Victory Capital Management Inc. now owns 218,531 shares of the company’s stock worth $10,605,000 after acquiring an additional 21,530 shares during the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price objective for the company. Piper Sandler cut shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $66.00 to $36.00 in a research report on Tuesday, February 4th.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.